Investing.com - ReShape Lifesciences (NASDAQ: RSLS) reported fourth quarter EPS of $-34.020, $21.52 worse than the analyst estimate of $-12.500. Revenue for the quarter came in at $2.29M versus the consensus estimate of $3.92M.
ReShape Lifesciences's stock price closed at $2.460. It is down -43.320% in the last 3 months and down -94.040% in the last 12 months.
ReShape Lifesciences saw 0 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See ReShape Lifesciences's stock price’s past reactions to earnings here.
According to InvestingPro, ReShape Lifesciences's Financial Health score is "weak performance".
Check out ReShape Lifesciences's recent earnings performance, and ReShape Lifesciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar